Serum GFAP and IGFBP-2 levels on mutated AKT/KRAS induced glioma in the mouse

AS S. NurFathiah, D. Kenny, Suzana Makpol, S. L. Holmen, AAJ A J Rahman, W. N. Wan Zurinah

Research output: Contribution to journalArticle

Abstract

Introduction: Glioblastomamultiforme is a highly malignant brain tumor which is categorized as invasive tumor due to poor prognosis and difficult to diagnose at earlier stage of the tumor. The development of an animal model for glioma using RCAS/TVA system is a powerful tool to address on gene function and therapy, tumorigenesis and oncogenesis. Objective: To develop an animal model for glioma using RCAS/TVA system and measure two proteins which are glial fibrillary artificial protein (GFAP) and insulin growth factor binding protein 2 (IGFBP2) as markers of the progression of glioma formation. Methods: Plasmid DNA carrying oncogenes of glioma (AKT and KRAS) was transformed into competent E.coli and the successful transformed plasmid DNA was extracted. The purity and concentration of plasmid DNA was obtained and cut by restriction enzyme (Hind III and Sma I). Then, plasmid DNA was transfected into chicken fibroblast DF-1 cell. The transfected DF-1 cell was confirmed by ALV p27 ELISA and western blot. Newborn mice carrying Nestin/. T-va strains at the age of 24 hours were injected with infected DF-1 cell and latency period to develop glioma was within 3-5 weeks after injection. Blood was obtained from the tail at the age of 4weeks until week 14. Serum GFAP and IGFBP2 were measured by ELISA. Result: Glioma was successfully developed in the mouse model using a mutated AKT/KRAS plasmid DNA. Serum GFAP and IGFBP2 were significantly higher in mice injected with infected DF-1 cell carrying oncogenes for glioma (p<0.05)compared to mice without injection. Conclusion: GFAP and IGFBP-2 have the potential as serum biomarkers for glioma in animal model. Thus, this reliable blood-based tumor biomarkers could significantly improve clinical diagnosis and research studies in glioma patients.

Original languageEnglish
Pages (from-to)238
Number of pages1
JournalAsian Pacific Journal of Tropical Disease
Volume4
Issue number3
DOIs
Publication statusPublished - Jun 2014

Fingerprint

Insulin-Like Growth Factor Binding Protein 2
Glioma
Neuroglia
Serum
Plasmids
Proteins
DNA
Intercellular Signaling Peptides and Proteins
Carrier Proteins
Animal Models
Insulin
Oncogenes
Carcinogenesis
Enzyme-Linked Immunosorbent Assay
Nestin
Injections
Tumor Biomarkers
Brain Neoplasms
Genetic Therapy
Tail

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Serum GFAP and IGFBP-2 levels on mutated AKT/KRAS induced glioma in the mouse. / NurFathiah, AS S.; Kenny, D.; Makpol, Suzana; Holmen, S. L.; Rahman, AAJ A J; Wan Zurinah, W. N.

In: Asian Pacific Journal of Tropical Disease, Vol. 4, No. 3, 06.2014, p. 238.

Research output: Contribution to journalArticle

NurFathiah, AS S. ; Kenny, D. ; Makpol, Suzana ; Holmen, S. L. ; Rahman, AAJ A J ; Wan Zurinah, W. N. / Serum GFAP and IGFBP-2 levels on mutated AKT/KRAS induced glioma in the mouse. In: Asian Pacific Journal of Tropical Disease. 2014 ; Vol. 4, No. 3. pp. 238.
@article{6fd34173ac504deea5976c293d2732c2,
title = "Serum GFAP and IGFBP-2 levels on mutated AKT/KRAS induced glioma in the mouse",
abstract = "Introduction: Glioblastomamultiforme is a highly malignant brain tumor which is categorized as invasive tumor due to poor prognosis and difficult to diagnose at earlier stage of the tumor. The development of an animal model for glioma using RCAS/TVA system is a powerful tool to address on gene function and therapy, tumorigenesis and oncogenesis. Objective: To develop an animal model for glioma using RCAS/TVA system and measure two proteins which are glial fibrillary artificial protein (GFAP) and insulin growth factor binding protein 2 (IGFBP2) as markers of the progression of glioma formation. Methods: Plasmid DNA carrying oncogenes of glioma (AKT and KRAS) was transformed into competent E.coli and the successful transformed plasmid DNA was extracted. The purity and concentration of plasmid DNA was obtained and cut by restriction enzyme (Hind III and Sma I). Then, plasmid DNA was transfected into chicken fibroblast DF-1 cell. The transfected DF-1 cell was confirmed by ALV p27 ELISA and western blot. Newborn mice carrying Nestin/. T-va strains at the age of 24 hours were injected with infected DF-1 cell and latency period to develop glioma was within 3-5 weeks after injection. Blood was obtained from the tail at the age of 4weeks until week 14. Serum GFAP and IGFBP2 were measured by ELISA. Result: Glioma was successfully developed in the mouse model using a mutated AKT/KRAS plasmid DNA. Serum GFAP and IGFBP2 were significantly higher in mice injected with infected DF-1 cell carrying oncogenes for glioma (p<0.05)compared to mice without injection. Conclusion: GFAP and IGFBP-2 have the potential as serum biomarkers for glioma in animal model. Thus, this reliable blood-based tumor biomarkers could significantly improve clinical diagnosis and research studies in glioma patients.",
author = "NurFathiah, {AS S.} and D. Kenny and Suzana Makpol and Holmen, {S. L.} and Rahman, {AAJ A J} and {Wan Zurinah}, {W. N.}",
year = "2014",
month = "6",
doi = "10.1016/S2222-1808(14)60541-7",
language = "English",
volume = "4",
pages = "238",
journal = "Asian Pacific Journal of Tropical Disease",
issn = "2222-1808",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Serum GFAP and IGFBP-2 levels on mutated AKT/KRAS induced glioma in the mouse

AU - NurFathiah, AS S.

AU - Kenny, D.

AU - Makpol, Suzana

AU - Holmen, S. L.

AU - Rahman, AAJ A J

AU - Wan Zurinah, W. N.

PY - 2014/6

Y1 - 2014/6

N2 - Introduction: Glioblastomamultiforme is a highly malignant brain tumor which is categorized as invasive tumor due to poor prognosis and difficult to diagnose at earlier stage of the tumor. The development of an animal model for glioma using RCAS/TVA system is a powerful tool to address on gene function and therapy, tumorigenesis and oncogenesis. Objective: To develop an animal model for glioma using RCAS/TVA system and measure two proteins which are glial fibrillary artificial protein (GFAP) and insulin growth factor binding protein 2 (IGFBP2) as markers of the progression of glioma formation. Methods: Plasmid DNA carrying oncogenes of glioma (AKT and KRAS) was transformed into competent E.coli and the successful transformed plasmid DNA was extracted. The purity and concentration of plasmid DNA was obtained and cut by restriction enzyme (Hind III and Sma I). Then, plasmid DNA was transfected into chicken fibroblast DF-1 cell. The transfected DF-1 cell was confirmed by ALV p27 ELISA and western blot. Newborn mice carrying Nestin/. T-va strains at the age of 24 hours were injected with infected DF-1 cell and latency period to develop glioma was within 3-5 weeks after injection. Blood was obtained from the tail at the age of 4weeks until week 14. Serum GFAP and IGFBP2 were measured by ELISA. Result: Glioma was successfully developed in the mouse model using a mutated AKT/KRAS plasmid DNA. Serum GFAP and IGFBP2 were significantly higher in mice injected with infected DF-1 cell carrying oncogenes for glioma (p<0.05)compared to mice without injection. Conclusion: GFAP and IGFBP-2 have the potential as serum biomarkers for glioma in animal model. Thus, this reliable blood-based tumor biomarkers could significantly improve clinical diagnosis and research studies in glioma patients.

AB - Introduction: Glioblastomamultiforme is a highly malignant brain tumor which is categorized as invasive tumor due to poor prognosis and difficult to diagnose at earlier stage of the tumor. The development of an animal model for glioma using RCAS/TVA system is a powerful tool to address on gene function and therapy, tumorigenesis and oncogenesis. Objective: To develop an animal model for glioma using RCAS/TVA system and measure two proteins which are glial fibrillary artificial protein (GFAP) and insulin growth factor binding protein 2 (IGFBP2) as markers of the progression of glioma formation. Methods: Plasmid DNA carrying oncogenes of glioma (AKT and KRAS) was transformed into competent E.coli and the successful transformed plasmid DNA was extracted. The purity and concentration of plasmid DNA was obtained and cut by restriction enzyme (Hind III and Sma I). Then, plasmid DNA was transfected into chicken fibroblast DF-1 cell. The transfected DF-1 cell was confirmed by ALV p27 ELISA and western blot. Newborn mice carrying Nestin/. T-va strains at the age of 24 hours were injected with infected DF-1 cell and latency period to develop glioma was within 3-5 weeks after injection. Blood was obtained from the tail at the age of 4weeks until week 14. Serum GFAP and IGFBP2 were measured by ELISA. Result: Glioma was successfully developed in the mouse model using a mutated AKT/KRAS plasmid DNA. Serum GFAP and IGFBP2 were significantly higher in mice injected with infected DF-1 cell carrying oncogenes for glioma (p<0.05)compared to mice without injection. Conclusion: GFAP and IGFBP-2 have the potential as serum biomarkers for glioma in animal model. Thus, this reliable blood-based tumor biomarkers could significantly improve clinical diagnosis and research studies in glioma patients.

UR - http://www.scopus.com/inward/record.url?scp=84896698490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896698490&partnerID=8YFLogxK

U2 - 10.1016/S2222-1808(14)60541-7

DO - 10.1016/S2222-1808(14)60541-7

M3 - Article

VL - 4

SP - 238

JO - Asian Pacific Journal of Tropical Disease

JF - Asian Pacific Journal of Tropical Disease

SN - 2222-1808

IS - 3

ER -